SinoMab BioScience Ret. on assets
What is the Ret. on assets of SinoMab BioScience?
The Ret. on assets of SinoMab BioScience Limited is -23.63%
What is the definition of Ret. on assets?
Return on assets indicates how profitable a company’s assets are in generating revenue. It is computed by dividing net income by average total assets.
ttm (trailing twelve months)
The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.
Ret. on assets of companies in the Health Care sector on HKSE compared to SinoMab BioScience
What does SinoMab BioScience do?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Companies with ret. on assets similar to SinoMab BioScience
- Nemaura Medical has Ret. on assets of -23.74%
- RA International PLC has Ret. on assets of -23.72%
- Spineway Societe Anonyme has Ret. on assets of -23.71%
- Cullen Resources has Ret. on assets of -23.70%
- Alpha HPA has Ret. on assets of -23.70%
- Kaleyra Inc has Ret. on assets of -23.69%
- SinoMab BioScience has Ret. on assets of -23.63%
- The Conygar Investment PLC has Ret. on assets of -23.63%
- BiVictriX Therapeutics plc has Ret. on assets of -23.62%
- Innovative Designs has Ret. on assets of -23.62%
- Integra Garments and Textiles has Ret. on assets of -23.59%
- Feedback plc has Ret. on assets of -23.59%
- Netscout Systems Inc has Ret. on assets of -23.55%